Cargando…
Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria
OBJECTIVES: Previous work showed that gag-protease-derived phenotypic susceptibility to PIs differed between HIV-1 subtype CRF02_AG/subtype G-infected patients who went on to successfully suppress viral replication versus those who experienced virological failure of lopinavir/ritonavir monotherapy a...
Autores principales: | Datir, R, El Bouzidi, K, Dakum, P, Ndembi, N, Gupta, R K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477990/ https://www.ncbi.nlm.nih.gov/pubmed/30726945 http://dx.doi.org/10.1093/jac/dkz005 |
Ejemplares similares
-
A23 Identification of HIV drug resistance mutation patterns using illumina MiSeq next generation sequencing in patients failing second-line boosted protease inhibitor therapy in Nigeria
por: James, Onyemata E., et al.
Publicado: (2017) -
In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
por: Datir, Rawlings, et al.
Publicado: (2020) -
Virological efficacy of PI monotherapy for HIV-1 in clinical practice
por: El Bouzidi, Kate, et al.
Publicado: (2016) -
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2020) -
Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
por: Pillay, D, et al.
Publicado: (2010)